Skip to main content
LOGIN
Solutions
Solutions
Solutions for Integrated Delivery Networks
Solutions for Community Cancer Centers
Solutions for Academic Institutions and NCI-Designated Cancer Centers
Solutions for Life Science
Resources
Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
About
About Us
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
Schedule A Demo
Solutions
Next Level Multidisciplinary Cancer Care Solutions for Cancer Centers, Oncology Practices and Life Science Organizations
Academic and NCI
Cancer Center Solutions
Leading institutions rely on OncoLens to drive clinical trial research, multidisciplinary care, and affiliate network engagement.
Community Cancer
Center Solutions
100+ community cancer centers and oncology practices use OncoLens to improve patient access to next level multidisciplinary care, accreditations, and quality improvement.
Integrated Delivery Network (IDN) Solutions
The OncoLens platform drives standardization and provider engagement across the entire network.
Life Sciences Solutions
Life Sciences Organizations work with OncoLens to collaborate with its oncology network, the largest in the United States.
Next Level
Multidisciplinary Cancer Care
Explore the OncoLens Platform
Schedule a Demo
Resources
Project ECHO® Learning Series
Evolving Role of Bispecific Antibodies as Cancer Therapy
Join ACCC, Physicians' Education Resource (PER), and Pharmacy Times Continuing Education (PTCE) for a five-part complimentary tele-mentoring series on the optimal use of bispecific antibodies as cancer immunotherapies.
LEARN MORE and REGISTER
OncoLens Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
OncoLens provides a first of its kind
multidisciplinary care platform.
More than 10% of all cancer centers in the United States count on OncoLens to help improve outcomes through coordinated patient data, in-depth analysis, and actionable clinical decision support.
2,000,000+
Patients under Care in 200+ Cancer Centers
143,000+
Multidisciplinary Case Discussions
24,000+
Comprehensive Tumor Conferences
About OncoLens
About Us
Meet Our Leadership Team
Awards
Meet Our Board of Directors
Contact Us
Careers
Schedule a Demo
Careers
Solutions
Next Level Multidisciplinary Cancer Care Solutions for Cancer Centers, Oncology Practices and Life Science Organizations
Academic and NCI
Cancer Center Solutions
Leading institutions rely on OncoLens to drive clinical trial research, multidisciplinary care, and affiliate network engagement.
Community Cancer
Center Solutions
100+ community cancer centers and oncology practices use OncoLens to improve patient access to next level multidisciplinary care, accreditations, and quality improvement.
Integrated Delivery Network (IDN) Solutions
The OncoLens platform drives standardization and provider engagement across the entire network.
Life Sciences Solutions
Life Sciences Organizations work with OncoLens to collaborate with its oncology network, the largest in the United States.
Next Level
Multidisciplinary Cancer Care
Explore the OncoLens Platform
Resources
Project ECHO® Learning Series
Expert-led telementoring sessions focused on irAE monitoring and management strategies for approved cancer immunotherapies.
LEARN MORE and REGISTER
Hosted by ACCC and Boston University. Sponsored by Bristol Myers Squibb.
Powered by OncoLens.
OncoLens Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
OncoLens provides a first of its kind
multidisciplinary care platform.
More than 10% of all cancer centers in the United States count on OncoLens to help improve outcomes through coordinated patient data, in-depth analysis, and actionable clinical decision support.
2,000,000+
Patients under Care in 200+ Cancer Centers
118,000+
Multidisciplinary Case Discussions
19,000+
Comprehensive Tumor Conferences
About OncoLens
About Us
Meet Our Leadership Team
Awards
Meet Our Board of Directors
Contact Us
Careers
Schedule A Demo
SCHEDULE A DEMO
LOGIN
Home
Resources
Education
Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion
Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion
Date Recorded:
February 1, 2021
Recording Length:
22:04
Topics:
EGFR
,
Exon 19 Deletion
,
lung cancer
,
NSCLC
Latest
Dec 14, 2023 | Blog
Rapid Identification of Cancer Patient Cohorts and Care Patterns With Generative AI
Read more
Sep 18, 2023 | Blog
Disappointing Clinical Trial Accruals – The Cancer Center Perspective
Read more
Aug 24, 2023 | News and Events
OncoLens Named to Inc. 5000 List of Fastest Growing Private Companies in America
Read more
Aug 10, 2023 | Blog
Strategies for Enhancing Hospital Programs’ Quality Metric Tracking for Accreditation
Read more
